Clinical Trials · NCT06383390
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)
- Phase
- Phase 3
- Recruitment status
- Active Not Recruiting
- Sponsor
- Eli Lilly and Company
- Enrollment
- 10,000
- Start date
- Apr 2024
- Locations
- 743 sites, 27 countries
- Primary endpoint
- Time to First Occurrence of Composite Endpoints